Protein tyrosine kinase inhibitors as novel therapeutic agents

Pharmacology and Therapeutics

Volumn 82, Issue 2-3, 1999, Pages 231-239

  Levitzki, Alexander ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Clinical trials; Drug development; Proliferative diseases; Protein tyrosine kinases; Tyrphostin inhibitors

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; AG 1385; AG 957; ANGIOGENESIS INHIBITOR; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; N (4 BUTYLPHENYL) ALPHA CYANOCAFFEIC ACID AMIDE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; TYRPHOSTIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLERGIC ENCEPHALOMYELITIS; ARTERY INJURY; BALLOON CATHETER; CANCER; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DESIGN; HUMAN; INFLAMMATORY DISEASE; LEUKEMIA; LIVER CIRRHOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PSORIASIS; RESTENOSIS; SEPSIS; SWINE;

DRUG DESIGN; ENZYME INHIBITORS; FORECASTING; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); PHOSPHORYLATION; PROTEIN-TYROSINE KINASES;

EID: 0033061032     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(98)00066-7     Document Type: Conference Paper

References (57)

1. Anafi M., Gazit A., Gilon C., Ben-Neriah Y., Levitzki A. Selective interactions of transforming and normal Abl proteins with ATP, tyrosine copolymer substrates and tyrphostins. J. Biol. Chem. 267:1992;4518-4523.
2. Bacus S.S., Zenick C.R., Plowman G., Varden Y. Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior. Am. J. Clin. Pathol. 102:1994;S13-S24.
3. Banai S., Wolf G., Golomb A., Pearle A., Waltenberger J., Fibstein I., Schneider A., Gazit A., Perez L., Huber R. PDGF-receptor tyrosine kinase blocker AG 1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointimal formation after balloon angioplasty in swine. Circulation. 19:1998;1960-1969.
4. Ben-Bassat H., Vardi D.V., Gazit A., Klaud S.N., Chaouat M., Hartzstark Z., Levitzki A. Tyrphostins suppress the growth of psoriatic keratinocytes. Exp. Dermatol. 4:1995;82-84.
5. Ben-Bassat H., Rosenbaum-Mitrani S., Hartzstark Z., Shlomai Z., Kleinberger-Doron N., Gazit A., Plowman G., Levitzki R., Tsvieli R., Levitzki A. Blockers of the EGF receptor and of Cdk2 activation induce growth arrest, differentiation, and apoptosis of HPV 16 immortalized human keratinocytes. Cancer Res. 57:1997;3741-3750.
6. Brenner T., Poradosu E., Soffer D., Sicsic C., Gazit A., Levitzki A. Suppression of experimental autoimmune encephalomyelitis by tyrphostin AG-556. Exp. Neurol. 154:1998;489-498.
7. Bridges A.J., Zhou H., Cody D.R., Rewcastle G.W., McMichael A., Showalter H.D.H., Fry D.W., Kraker A.J., Denny W.A. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035). A potent inhibitor of the epidermal growth factor receptor. J. Med. Chem. 39:1996;267-276.
8. Buchdunger E., Mett H., Trinks U., Regenass U., Muller M., Meyer T., Beilstein P., Wirz B., Schneider P., Traxler P. 4,5-Bis(4-fluoroanilino)phthalimide. a selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity Clin. Cancer Res. 1:1995;813-821. a.
9. Buchdunger E., Zimmermann J., Mett H., Meyer T., Muller M., Regenass U., Lydon N. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. USA. 92:1995;2558-2562. b.
10. + chronic myelogenous leukemia progenitor cells. Blood. in press:1999.
11. Carroll M., Tomasson M., Barker G., Golub T., Gillialand D. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways. Proc. Natl. Acad. Sci. USA. 10:1996;14845-14850.
12. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernandez-Luna J.L., Nunez G., Dalton W.S., Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 10:1999;105-115.
13. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med. 2:1996;561-566.
14. Dvir A., Milner Y., Chomsky O., Gilon C., Gazit A., Levitzki A. The inhibition of EGF-dependent proliferation of keratinocytes by tyrosine kinase blockers. J. Cell Biol. 113:1991;857-865.
15. Fry D.W., Kraker A.J., McMichael A., Ambroso L.A., Nelson J.M., Leopold W.R., Connors R.W., Bridges A.J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science. 265:1994;1093-1095.
16. Gazit A., App H., McMahon G., Chen J., Levitzki A., Bohmer F.D. Tyrphostin. 5. Potent inhibitors of PDGF receptor tyrosine kinase. SAR in quinixalines, quinolines and indole tyrphostins. J. Med. Chem. 39:1996;2170-2177. a.
17. Gazit A., Chen J., App H., McMahon G., Hirth P., Chen I., Levitzki A. Tyrphostin. 4. Highly potent inhibitors of EGF receptor kinase. Structure activity relationship study of 4-anilido quinazolines. Bioorg. Med. Chem. 8:1996;1203-1207. b.
18. Golomb G., Fishbein I., Banai S., Mishaly D., Msocovitz D., Gertz D., Gazit A., Levitzki A. Controlled delivery of a tyrphostin inhibits intimal hyperplasia in rat carotid artery injury model. Atherosclerosis. 125:1996;171-182.
19. Groundwater P.W., Solomons K.R.H., Drewe J.A., Munawar M.A. Protein tyrosine kinase inhibitors. Prog. Med. Chem. 33:1996;233-329.
20. Han Y., Caday C.G., Nanda A., Cavenee W.K., Su Hunag H.-J. Tyrphostin AG 1478 preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors. Cancer Res. 56:1996;3859-3861.
21. Hubbard S.R. Crystal structure of the activated insulin receptor tyrosine kinase, in complex with peptide substrate and ATP analog. EMBO J. 16:1997;5572-5581.
22. Hubbard S.R., Wei L., Ellis L., Hendrickson W.A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature. 372:1994;746-754.
23. Indolfi C., Avvedimento E.V., Rapacciuolo A., Di Lorenzo E., Esposito G., Stabile E., Feliciello A., Mele E., Giuliano P., Condorelli G., Chiariello M. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nature Med. 1:1995;541-545.
24. bcr-abl autokinase activity in K562 chronic myelogenous leukemia Anticancer Drugs. 5:1994;213-222.
25. Kelly S.A., Goldschmidt-Clermont P.J., Milliken E., Arai T., Smith E.H., Bulkley G.B. Protein tyrosine phosphorylation mediated TNF-induced endothelial-neutrophil adhesion in vitro. Am. J. Physiol. (Heart Circ. Physiol.). 43:1998;H513-H519.
26. Kovalenko M., Gazit A., Bohmer A., Rorsman C., Ronnstrand L., Heldin C., Waltenberger J., Böhmer F.D., Levitzki A. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 54:1994;6106-6114.
27. Kovalenko M., Romstrand L., Heldin C.-H., Loubochenko M., Gazit A., Levitzki A., Bohmer F.D. Phosphorylation site-specific inhibition of platelet-derived growth factor b-receptor autophosphorylation by the receptor blocking tyrphostin AG 1296. Biochemistry. 36:1997;6260-6269.
28. Levitzki A. Tyrphostins. tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction FASEB J. 6:1992;3275-3282.
29. Levitzki A. Signal transduction therapy. Eur. J. Biochem. 226:1994;1-13.
30. Levitzki A. SRC as a target for anti-cancer drugs. Anticancer Drug Des. 11:1996;175-182. a.
31. Levitzki A. Targeting signal transduction for disease therapy. Curr. Opin. Cell. Biol. 8:1996;239-244. b.
32. Levitzki A. Targeting signal transduction for disease therapy. Med. Oncol. 14:1997;83-89.
33. Levitzki A., Bohmer F.D. Altered efficacy and selectivity of tyrosine kinase inhibitors of the activated states of protein tyrosine kinases. Anticancer Drug Des. 13:1998;731-734.
34. Levitzki A., Gazit A. Tyrosine kinase inhibition. an approach to drug development Science. 267:1995;1782-1788.
35. Lopez-Talavera J.C., Levitzki A., Martinez A., Gazit A., Esteban E., Guardian J. Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites. J. Clin. Invest. 100:1997;664-670.
36. Meydan N., Grunberger T., Dadi H., Shahar M., Arpaia E., Lapidot Z., Leader S., Freedman M., Cohen A., Gazit A. Inhibition of recurrent human pre-B acute lymphoblastic leukemia by Jak-2 tyrosine kinase inhibitor. Nature. 379:1996;645-648.
37. Mohammadi M., McMahon G., Sun L., Tang C., Hirth P., Yeh B.K., Hubbard S.R., Schlessinger J. Structure of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science. 276:1997;955-960.
38. Nagane M., Levitzki A., Cavenee W.K., Su Huang H.-J. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc. Natl. Acad. Sci. USA. 95:1998;5724-5729.
39. Novogrodsky A., Vanichkin M., Patya A., Gazit N., Osherov N., Levitzki A. Prevention of LPS-induced lethal toxicity by tyrosine kinase blockers. Science. 264:1994;1319-1322.
40. Osherov N., Levitzki A. Epidermal growth factor dependent activation of Src family kinases. Eur. J. Biochem. 225:1994;1047-1053.
41. Parrizas M., Gazit A., Levitzki A., Wertheimer E., LeRoith D. Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological functions by tyrphostins. Endocrinology. 138:1997;1427-1433.
42. Posner I., Engel M., Levitzki A. Kinetic model for the epidermal growth factor (EGF) receptor tyrosine kinase and a possible mechanism of its activation by EGF. J. Biol. Chem. 267:1992;20638-20647.
43. Posner I., Engel M., Gazit A., Levitzki A. Kinetics of inhibition of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program. Mol. Pharmacol. 45:1994;673-683.
44. Rewcastle G.W., Palmer B.D., Bridges A.J., Showalter H.D., Ross R. The pathogenesis of atherosclerosis - an update. N. Engl. J. Med. 314:1986;488-500.
45. Ross R., Glomset J.A. The pathogenesis of atherosclerosis. N. Engl. J. Med. 295:1976;369-377.
46. Schindler T., Sicheri F., Pico A., Gazit A., Levitzki A., Kuriyan J. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell. in press:1999.
47. Sevransky J.E., Shaked G., Novogrodsky A., Levitzki A., Gazit A., Hoffman Z., Quezado B.D. Tyrphostin AG 556 improves survival and reduces multiorgan failure in canine E. coli peritonitis. J. Clin. Invest. 99:1997;1966-1973.
48. Sharfe N., Dadi H.K., Roifman C.M. JAK 3 protein kinase mediates interleukin-7 induced activation of phosphatidyl insositol-3-kinase. Blood. 86:1995;2077-2085.
49. Sicheri F., Moarefi I., Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature. 385:1997;602-609.
50. Strawn L.M., McMahon G., App H., Schreck R., Kuchler W.R., Longhi M.P., Hui T.-H., Tang C., Levitzki A., Gazit A., Chen I., Keri G., Orfi L., Risau W., Flamme I., Ullrich A., Hirth K.P., Shawver L.K. Flk-1 as a target for tumor growth inhibition. Cancer Res. 56:1996;3540-3545.
51. Sun L., Nelson J., McMichael A., Kraker A.J., Fry D.W., Denny W.A. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 39:1996;918-928.
52. Traxler P.M., Furet P., Mett H., Buchdunger E., Meyer T., Lydon N. 4-(Phenylamino)pyrrolopyrimidines. potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase J. Med. Chem. 39:1996;2285-2292.
53. Tsai C.M., Levitzki A., Wu L.-H., Chang K.-T., Cheng C.-C., Gazit A., Pemg R.-P. Enhancement of chemosensitivity by tyrphostin AG 825 in high-p185neu expressing non-small cell lung cancer cells. Cancer Res. 56:1996;1068-1074.
54. Vanichkin A., Palya M., Gazit A., Levitzki A., Novogrodsky A. Late administration of a lipophilic tyrosine kinase inhibitor prevents lipopolysacharide and Escherichia coli-induced lethal toxicity. J. Infect. Dis. 173:1996;927-933.
55. Ward W.H.J., Cook P.N., Slater A.M., Davies D.H., Holdgate G.A., Gree L.R. Epidermal growth factor receptor tyrosine kinase investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 48:1994;639-666.
56. Yaish P., Gazit A., Gilon C., Levitzki A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science. 242:1988;933-935.
57. Yoneda T., Lyall R.M., Alisina M.M., Pearsons P.E., Spada A.P., Levitzki A., Zilberstein A., Mundy G.R. The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res. 51:1991;4430-4435.